血管内皮生长因子与骨巨细胞瘤预后的关系  

Relationship between Vascular Endothelial Growth Factor and Prognosis of Giant Cell Tumor of Bone

作　　者：王华[1] 顾洁夫[1] 蔡林[1] 陈廖斌[1] 

机构地区：[1]武汉大学中南医院骨科,武汉430071

出　　处：《武汉大学学报（医学版）》2005年第4期517-519,共3页Medical Journal of Wuhan University

摘　　要：目的:研究血管内皮生长因子(VEGF)及微血管密度(MVD)对估计人骨巨细胞瘤预后的价值。方法:通过对69例骨巨细胞瘤患者的随访,将他们分为无复发和无转移组及复发或转移组。采用免疫组织化学SABC法检测骨巨细胞瘤中VEGF、CD34的表达,用MVD值衡量CD34的表达。结果:无复发组42例的中位阳性细胞率为28%,复发转移组27例的中位阳性细胞率为48%,两组间差别有极显著性意义(P<0.001)。无复发组MVD值为33.55±10.82,复发转移组MVD值为56.78±16.17,两组间MVD值的差别有极显著性意义(P<0.001)。VEGF阳性细胞率与MVD值的关系经Spearman等级相关检验,两者呈显著正相关(r=0.845,P<0.01)。结论:VEGF和MVD是估计骨巨细胞瘤预后的新指标,VEGF是重要的促血管生成因子。Objective: To analyze the degree of angiogenesis in nonrecurrent and recurrent giant cell tumor (GCT) of bone by immunohistochemical methods and to determine if VEGF and MVD could be used to predict the prognosis of GCT of bone. Methods: 69 patients who suffered giant cell tumor of bone were divided into non-recurrent group (NR-GCT group, 42 cases) and recurrent group (R-GCT group, 27 cases) by long-term follow-up. Paraffin embedded tissue from all 69 cases were stained with a polyclonal antibody against a peptide mapping at the amino terminus of VEGF and QBEND-10, a monoclonal antibody against CD34 (endothelial antigen). The number of cells exhibiting VEGF positive staining from 100 cells under 400× fields. The Weidner’s method was applied respectively for counting microvessel density. Results: The median for the positive rate of VEGF was 28% in NR-GCT group versus 48% in R-GCT with significant difference (P<0.001). MVD counts was 33.55± 10.82 in NR-GCT group versus 56.78±16.17 in R-GCT with significant difference (P<0.001). A relationship was defined between VEGF expression and MVD counts (r=0.845, P<0.01). Conclusion: This study presents the evidence that the degree of VEGF expression and MVD counts are useful parameters to predict the recurrence of GCT of bone. VEGF is involved in the angiogenesis of GCT of bone.

关 键 词：骨巨细胞瘤 血管内皮生长因子(VEGF) 预后 免疫组织化学SABC法 微血管密度(MVD) 促血管生成因子 CD34 转移组 无复发 细胞率 相关检验 显著性 D值 阳性 正相关 中位 差别 

分 类 号：R738.1[医药卫生—肿瘤] R446.61[医药卫生—临床医学]